Tavros Therapeutics, a Durham, N.C-based precision oncology platform company, raised $7.5M in Seed II funding.
The round was co-led by Piedmont Capital Investments and KdT Ventures, with participation from Alexandria Venture Investments.
The company intends to use the funds to continue developing its proprietary platform to identify synthetically lethal interactions to improve cancer care,
Led by CEO Eoin McDonnell, Tavros therapeutics leverages functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and help clinically position existing and new molecules with biomarker-driven strategies in areas of high unmet clinical need. The company’s bi-directional synthetic lethality platform can precisely and directly identify the paired genetic interactions that form the basis for targets and cancer drugs. Functional genomics and computational analysis accelerate the discovery of de-risked, druggable targets with the ultimate goal of improving patient outcomes, minimizing toxicity and quickening development in defined patient subsets. A strategic partnership with Zentalis Pharmaceuticals has validated the platform and expanded the company’s clinical impact. Tavros is also leveraging its proprietary platform and map of useful synthetic lethal relationships to build a pipeline of category-defining small-molecule drug candidates.
Tavros launched in 2020 with a $3m seed financing by Piedmont Capital Investments and a strategic collaboration with Zentalis Pharmaceuticals, Inc. to develop novel targeted small molecule drug candidates.
FinSMEs
28/09/2022